Advertisement

Topics

Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing ...

01:00 EDT 22 Jun 2017 | BioMedReports - Blog

"With its clinical profile and physiology, VEYVONDI is a first-of-its-kind treatment for VWD," said Alice Dietrich, MD, Head of Global Medical Affairs, Shire. "We're

Read more...

Original Article: Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing ...

NEXT ARTICLE

More From BioPortfolio on "Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing ..."

Advertisement
Quick Search
Advertisement
Advertisement